Friday, November 20, 2026

Understanding China. Seeing what’s next.

Understanding China. Seeing what’s next.

China’s richest bottled-water tycoon is pouring 1 billion yuan into medical aesthetics. Here is why

China’s bottled-water tycoon Zhong Shanshan, who controls beverage giant Nongfu Spring, has made a sweeping move into the medical aesthetics sector through his parent company, Wantong-backed health conglomerate Yangshengtang.

According to a public filing released on the evening of October 20, Yangshengtang initiated a massive share-acquisition plan targeting Jinbo Bio, a high-end biomedical firm specializing in human-like collagen. The deal carries a heavy penalty if performance benchmarks are missed, signaling a high-stakes bet by China’s most prominent industrialist.

Under the strategic agreement, Yangshengtang—which is 98.38% owned by Zhong—has committed to buying at least 1 billion yuan ($138 million) worth of Jinbo Bio shares on the secondary market within 18 months. Crucially, the agreement stipulates that if Yangshengtang fails to fulfill the 1-billion-yuan quota by the deadline, the company must pay the remaining cash shortfall directly to Jinbo Bio within a month as a dedicated donation for its collagen research and database development platform.

Jinbo Bio is led by founder Yang Xia, a former chemistry teacher at Shanxi Medical University who has risen to become one of Shanxi province’s wealthiest self-made women, with an estimated fortune of 17.0 billion yuan. The company develops type-A recombinant human-like collagen utilized in professional anti-aging injections, plastic surgery, and medical wound repairs.

China's richest bottled-water tycoon is pouring 1 billion yuan into medical aesthetics. Here is why

Photo / Visual China

Market analysts note that the partnership bridges a clear strategic gap between the two enterprises. While Jinbo Bio dominates medical-grade professional channels, its recent financial reports show slight headwinds—reporting a 7.71 billion yuan revenue scale in the first half of the year, down 10.20% year-on-year, alongside a 28.20% drop in net profit attributable to parent shareholders amid rising production costs and tighter market competition.

Yangshengtang brings deep commercial firepower to the table. Beyond its controlling stakes in Nongfu Spring and vaccine maker Wantong Wantai Biological Pharmacy Enterprise, Yangshengtang operates a sprawling retail distribution network spanning over 3 million outlets across China, alongside a quietly expanding high-end skincare division featuring premium lines priced above 1,000 yuan.

By leveraging Yangshengtang’s vast retail, e-commerce, and pharmaceutical distribution networks, Jinbo Bio aims to scale past clinical medical environments and push aggressively into the everyday consumer health and personal care market. Yangshengtang has already dispatched board representatives to participate directly in Jinbo Bio’s daily management operations.

The market responded enthusiastically to the announcement. Jinbo Bio shares surged 10.82% to close at 153.15 yuan on October 20, pushing the company’s total market capitalization to 177.49 billion yuan.

Leave a Reply

Your email address will not be published. Required fields are marked *